- Home
- DEA vs OPK Comparison
DEA vs OPK Comparison
Compare DEA & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- OPK
- Stock Information
- Founded
- DEA 2011
- OPK 2007
- Country
- DEA United States
- OPK United States
- Employees
- DEA N/A
- OPK N/A
- Industry
- DEA Real Estate Investment Trusts
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- OPK Health Care
- Exchange
- DEA Nasdaq
- OPK Nasdaq
- Market Cap
- DEA 1.0B
- OPK 1.1B
- IPO Year
- DEA 2015
- OPK 1995
- Fundamental
- Price
- DEA $22.89
- OPK $1.37
- Analyst Decision
- DEA Hold
- OPK Buy
- Analyst Count
- DEA 5
- OPK 4
- Target Price
- DEA $27.15
- OPK $2.75
- AVG Volume (30 Days)
- DEA 443.7K
- OPK 2.6M
- Earning Date
- DEA 08-05-2025
- OPK 08-06-2025
- Dividend Yield
- DEA 7.90%
- OPK N/A
- EPS Growth
- DEA N/A
- OPK N/A
- EPS
- DEA 0.41
- OPK N/A
- Revenue
- DEA $314,385,000.00
- OPK $689,408,000.00
- Revenue This Year
- DEA $7.80
- OPK N/A
- Revenue Next Year
- DEA $8.54
- OPK $6.98
- P/E Ratio
- DEA $55.77
- OPK N/A
- Revenue Growth
- DEA 6.82
- OPK N/A
- 52 Week Low
- DEA $19.33
- OPK $1.21
- 52 Week High
- DEA $36.31
- OPK $2.04
- Technical
- Relative Strength Index (RSI)
- DEA 51.70
- OPK 51.75
- Support Level
- DEA $22.31
- OPK $1.34
- Resistance Level
- DEA $23.38
- OPK $1.45
- Average True Range (ATR)
- DEA 0.53
- OPK 0.05
- MACD
- DEA -0.03
- OPK 0.00
- Stochastic Oscillator
- DEA 44.96
- OPK 38.46
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.